Skip to content
HeyJared

Indrajit Bandyopadhyay

Reporter

Indexed articles, last 90 days
3
Latest publication
Aug 24, 2026
Outlet visibility, for yahoo.com
Top 1K sites
Earliest in this view
Aug 24, 2026
The latest indexed work is over 30 days old. There may be a gap in what we hold.

Latest articles

  1. Article · Aug 24, 2026 · Indrajit Bandyopadhyay

    GEHC Q2 Orders Surge 11.1% as Record Backlog Builds 2027 Visibility (opens the original)

    Excerpt · English

    Read excerpt

    GE HealthCare Technologies Inc. GEHC delivered a notable demand signal in the second quarter, with organic orders rising 11.1% year over year. Book-to-bill reached 1.15X and backlog climbed to a record $23.9 billion. The key question is how much of that demand can convert into profitable revenues. Backlog visibility is improving, but execution in Patient Care Solutions and inflation remain important constraints. Management said second-quarter order growth was broad based across every segment and

  2. Article · Aug 24, 2026 · Indrajit Bandyopadhyay

    Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation? (opens the original)

    Excerpt · English

    Read excerpt

    McKesson Corporation MCK enters fiscal 2027 with double-digit earnings growth, faster expansion in specialty businesses and sizable capital returns. Those strengths support the long-term case, but the shares now trade above important historical and industry valuation benchmarks. That leaves investors with a tighter decision. The operating story is improving, yet the current multiple leaves less room for execution misses, policy changes or a slowdown in earnings momentum. McKesson raised fiscal 2

  3. Article · Aug 24, 2026 · Indrajit Bandyopadhyay

    McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate (opens the original)

    Excerpt · Neutral tone · English

    Read excerpt

    McKesson Corporation MCK opened fiscal 2027 with an earnings beat, double-digit adjusted operating profit growth and higher full-year earnings guidance. The quarter sharpened the focus on oncology, specialty distribution and GLP-1 volumes as profit drivers. The investor question is whether those engines can keep expanding earnings while lower branded-drug pricing, cash-flow timing and the planned Medical-Surgical separation create offsets. First-quarter adjusted earnings rose 20% to $9.93 per sh

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 1K sites

For yahoo.com, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Indrajit Bandyopadhyay